Health Care Delivery

Latest News


CME Content


What we're reading, December 23, 2015: CMS releases data on the most expensive Medicare drugs, while HHS reports strong enrollment numbers on HealthCare.gov, and Hillary Clinton outlines a plan to spend $20 billion on Alzheimer's disease research.

Democrats and Republicans agreeing on something having to do with the Affordable Care Act is unusual, but there is one aspect of the healthcare law that both parties feel the same about: the excise, or Cadillac, tax.

What we're reading, December 17, 2015: Congress is expected to pass a spending plan that includes 3 changes to the Affordable Care Act; a new analysis estimates 2016 premiums for marketplace plans will increase 11%; and one-third of Americans die from cardiovascular disease.

What we're reading, December 16, 2015: a new study casts doubt on what experts thought they knew about healthcare costs; unprecedented interest in health insurance coverage has prompted the government to extend the deadline for full-year 2016 coverage; and a law to create multi-state health plans won't reach it's 2017 goal.

While cost is an important component of value, it tells only a small part of the cancer care story. By focusing on issues of payment and cost alone, we miss our opportunity to engage cancer care stakeholders in the process of creating a more effective system of care.

What we're reading, December 15, 2015: call centers overwhelmed by last-minute rush for health insurance enrollment; AstraZeneca exploring deal with Acerta Pharma; and despite near universal health insurance coverage in Massachusetts, patients have access issues.

This week in managed care, an analysis found the penalty for being uninsured will exceed the cost of insurance for most Americans in 2016, thousands met for the annual meeting of the American Society of Hematology, and Horizon Blue Cross Blue Shield's OMNIA plan gets good news and bad news in New Jersey.

When considering how to rectify the rising prices of drugs, there are a number of interventions at multiple levels that can work to decrease costs to patients and the price of the drug, explained Yousuf Zafar, MD, MHS, associate professor in the Division of Medical Oncology at Duke Cancer Institute.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo